RxDoctor Payments Data

Eugene Chang, MD

Cardiovascular Disease · Marysville, WANPI 1992199459

Payments from drug & device makers

$5,031in general payments, 2019–2025

Across 89 payments — averaging $56.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Heartflow, Inc.$1K
  • Abbott$555
  • Pfizer$243
  • GE HealthCare$194
  • Cleerly, Inc.$154
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$1,51430%
  • Food & beverage$3,28065%
  • Education$2295%
  • Gifts$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,031 in reported general payments places this provider in the 75th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$303,700
Medicare patients
1,312
Services billed
14,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$278,548
JardianceEmpagliflozin57$66,913
XareltoRivaroxaban28$42,981
EntrestoSacubitril/Valsartan32$39,311
Repatha SureclickEvolocumab15$19,333
Praluent PenAlirocumab20$12,937
Metoprolol Succinate728$7,717
Rosuvastatin Calcium401$6,088
Atorvastatin Calcium436$4,796
Ezetimibe131$3,055
Nitroglycerin304$2,797
Amlodipine Besylate218$1,534
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$1,203
Lisinopril147$1,090
Spironolactone159$1,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$278,548206 claims
Johnson & JohnsonXarelto$85$42,98128 claims
NovartisEntresto$35$39,31132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Marysville

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →